Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Aceclidine · Vizz, NSC-657843

Small molecule · Agonist of Muscarinic acetylcholine receptor · developed by Lenz Therap

Approved FDA, Jul 2025
LENZ Developer
2 Registered trials

What is Aceclidine?

Aceclidine is a cholinergic muscarinic agonist that stimulates muscarinic receptors on smooth muscle. It is a predominantly pupil-selective miotic that acts on the iris sphincter muscle, causing contraction that produces a pinhole effect. It is studied in presbyopia and other refractive error and eye conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vizz, NSC-657843, NSC-758239
Drug type
Small molecule
Targets
Muscarinic acetylcholine receptor
Mechanism
Agonist of Muscarinic acetylcholine receptor
Pathways
Iris sphincter muscle contraction (miosis), Pinhole effect extending depth of focus
Therapy area
Ophthalmology
Developer
Lenz Therap (LENZ)
FDA status
Approved as Vizz (July 31, 2025), NDA218585 · FDA label
UNII
0578K3ELIO

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 14, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05728944 Phase 3 Presbyopia Completed LENZ
NCT03201562 Phase 2 Presbyopia Completed LENZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Eye DiseasesNear VisionPresbyopiaRefractive Error

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LENZ page.

Follow LENZ, the company behind Aceclidine

See LENZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LENZ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.